We'd all like to invest like the legendary Warren Buffett, turning thousands into millions or more. Buffett analyzes companies by calculating return on invested  capital (ROIC) to help determine whether a company has an economic moat -- the ability to earn returns on its money above that money's cost.  

ROIC is perhaps the most important metric in value investing. By determining a company's ROIC, you can see how well it's using the cash you entrust to it and whether it's actually creating value for you. Simply, ROIC divides a company's operating profit by how much investment it took to get that profit. The formula:

ROIC = Net operating profit after taxes / Invested capital

(You can read more on the nuances of the formula.)

This one-size-fits-all calculation cuts out many of the legal accounting tricks, such as excessive debt, that managers use to boost earnings numbers, and it provides you with an apples-to-apples way to evaluate businesses, even across industries. The higher the ROIC, the more efficiently the company uses capital.

Ultimately, we're looking for companies that can invest their money at rates that are higher than the cost of capital, which for most businesses is between 8% and 12%. We prefer to see ROIC above 12% at a minimum, along with a history of increasing returns, or at least steady returns, which indicate some durability to the company's economic moat.

Let's look at Amgen (Nasdaq: AMGN) and two of its industry peers, to see how efficiently they use cash. Here are the ROIC figures for each company over a few periods.

Company

TTM

1 Year Ago

3 Years Ago

5 Years Ago

Amgen 22.4% 22.2% 18.6% 18.1%
Novartis (NYSE: NVS) 10.8% 14.5% 13.0% 15.2%
Sanofi-Aventis (NYSE: SNY) 9.3% 8.8% 8.5% 5.4%

Source: Capital IQ, a division of Standard & Poor's.

Amgen has shown consistently increasing returns on invested capital in each period here, suggesting that its competitive position is growing stronger. Novartis, on the other hand, has seen a decline in its ROIC from one, three, and five years ago. Sanofi hasn't consistently reached our threshold for attractiveness, although its ROIC has climbed each period here, suggesting its position is improving.

Businesses with consistently high ROIC show that they're efficiently using capital. They also have the ability to treat shareholders well, because they can then use their extra cash to pay out dividends to us, buy back shares, or further invest in their franchise. And healthy and growing dividends are something that Warren Buffett has long loved.

So for more successful investments, dig a little deeper than the earnings headlines to find the company's ROIC. If you'd like, you can add these companies to your watchlist.

Jim Royal, Ph.D., owns no shares in any company mentioned. Novartis is a Motley Fool Global Gains choice. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.